BIOAHealthcare · Drug Manufacturers - Specialty & GenericThe 9 Wall Street analysts covering BioAge Labs, Inc. hold a median 12-month price target of $38 — +247.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 1 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores BioAge Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (76): Analysts have, on balance, been raising their forecasts.
Volatility (19): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own BioAge Labs, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on BIOA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +247.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | Needham | Maintains | Buy | $50 → $35 |
| 27 May 2026 | Roth Capital | Initiates | Buy | $36 |
| 27 May 2026 | Roth Capital | Initiates | Buy | — |
| 13 May 2026 | BTIG | Initiates | Buy | — |
| 27 Mar 2026 | Needham | Initiates | Buy | — |
| 10 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Feb 2026 | Oppenheimer | Initiates | Outperform | — |
| 18 Feb 2026 | Jefferies | Upgrade | Buy | — |
| 27 Jan 2026 | Piper Sandler | Initiates | Overweight | — |
| 8 Dec 2025 | Morgan Stanley | Upgrade | Equal-Weight | — |
| 29 Oct 2025 | Citigroup | Maintains | Buy | — |
| 22 Oct 2025 | Citigroup | Upgrade | Buy | — |
| 24 Mar 2025 | Citigroup | Maintains | Neutral | — |
| 7 Mar 2025 | Morgan Stanley | Assumes | Underweight | $5.00 |
| 28 Feb 2025 | William Blair | Initiates | Market Perform | — |
| 9 Dec 2024 | Citigroup | Downgrade | Neutral | — |
| 9 Dec 2024 | Jefferies | Downgrade | Hold | — |
| 21 Oct 2024 | Citigroup | Initiates | Buy | $45 |
| 21 Oct 2024 | Jefferies | Initiates | Buy | $42 |
| 21 Oct 2024 | Morgan Stanley | Initiates | Overweight | $40 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 6% of US stocks
Cheaper than 71% of US stocks
Cheaper than 63% of US stocks
Higher than 93% of US stocks
Higher than 85% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 29% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIOA appears on the weeks it earns a place.
BioAge Labs stock fell Friday after Novo Nordisk reported disappointing Phase 3 cardiovascular trial results, raising concerns about the potential of NLRP3-targeting therapies.
Why it matters — A BIOA watcher would care because the negative read-through from Novo Nordisk's trial outcome may reflect on the broader prospects for the NLRP3-targeting approach that BioAge Labs is involved with.
The 9 Wall Street analysts covering BioAge Labs, Inc. have a median 12-month price target of $38, with estimates ranging from $21 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering BioAge Labs, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioAge Labs, Inc. 40 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, BioAge Labs, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (76 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +247.9% from the last close, and Ticker Nerd's factor model ranks BioAge Labs, Inc. 40 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioAge Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIOA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $73 over the next 12 months.
BioAge Labs, Inc. returned +161.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
BioAge Labs Inc. is a biotechnology company focused on discovering and developing therapies that can enhance the human lifespan and address age-related diseases.
The most recent item we track (Benzinga, 31 July 2026): "Why Is BioAge Labs Stock Sinking Friday?". BioAge Labs stock fell Friday after Novo Nordisk reported disappointing Phase 3 cardiovascular trial results, raising concerns about the potential of NLRP3-targeting therapies.
BioAge Labs Inc. is a biotechnology company focused on discovering and developing therapies that can enhance the human lifespan and address age-related diseases. By leveraging advanced technologies like artificial intelligence and genomics, BioAge Labs aims to pinpoint key molecular drivers of aging. Its approach involves identifying biological pathways that extend healthy lifespan, then discovering compounds that can influence these pathways to develop innovative treatments for age-associated conditions such as cancer, cardiovascular diseases, and metabolic disorders. BioAge Labs conducts research that spans various stages, from preclinical studies to early-stage clinical trials, frequently collaborating with leading scientific institutions and pharmaceutical partners. Operating within the biopharmaceutical industry, the company's work significantly impacts healthcare and wellness sectors by potentially altering age-related disease progression and improving quality of life for aging populations. As part of the burgeoning field of biotechnology focusing on longevity, BioAge Labs holds a notable place in the financial market by engaging in an area of medicine that combines cutting-edge bioinformatics with traditional biopharmaceutical research and development.
CEO Dr. Kristen Fortney Ph.D. · 60 employees · United States · https://bioagelabs.com